- Home
- ANIX vs FORA Comparison
ANIX vs FORA Comparison
Compare ANIX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | FORA |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 69.4M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | FORA |
|---|---|---|
| Price | $3.27 | $2.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 353.5K | 36.0K |
| Earning Date | 01-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $2.07 | $1.64 |
| 52 Week High | $5.46 | $4.03 |
Technical Indicators
Market Signals| Indicator | ANIX | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 47.03 |
| Support Level | $4.20 | $2.11 |
| Resistance Level | $5.46 | $2.19 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 2.77 | 55.00 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.